Please upgrade your browser.
nce the approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC).
Statin use at the time of surgery is associated with improved overall survival (OS) and disease-specific survival (DSS) in patients with renal cell carcinoma (RCC) of any stage, US researchers report.
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.
The KCA has earned its seventh consecutive 4-star rating from Charity Navigator
Kidney Cancer Association Patient and Survivor Conference to be Held in North Carolina December 13, 2014
The University of North Carolina will be hosting its second conference for kidney cancer patients and their families on Saturday, December 13, 2014.
Top-Line Data from METEOR Expected in Q2 2015
Data from the study will be presented during the Plenary Session at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology.
Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease, which currently has few treatment options.
The Genentech Access to Care Foundation (GATCF), which provides Genentech medicines for free to people without insurance, is changing its eligibility criteria with the goal of helping more people who may be having trouble accessing Genentech medicines.
When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.
|Powered by NeonCRM|